Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.
Type:
Application
Filed:
December 21, 2023
Publication date:
December 12, 2024
Applicants:
Indivior UK Limited, Aegis Therapeutics, LLC
Inventors:
Roger CRYSTAL, Arvind AGRAWAL, Edward T. MAGGIO
Abstract: Drug products adapted for nasal delivery, comprising a device filled with a pharmaceutical composition comprising naltrexone are provided. Formulations and methods of treating alcohol use disorder and related conditions with the drug products are also provided.
Type:
Application
Filed:
December 21, 2023
Publication date:
December 12, 2024
Applicants:
Aegis Therapeutics, LLC, Indivior UK Limited
Inventors:
Edward T. MAGGIO, Roger CRYSTAL, Mark ELLISON, Phil SKOLNICK, Arvind AGRAWAL
Abstract: Formulations and methods for the preventative treatment of incidental opioid overdose comprising the intranasal (IN) administration of a pharmaceutical formulation containing the opioid antagonist nalmefene as a prophylactic measure.
Type:
Application
Filed:
February 8, 2024
Publication date:
June 20, 2024
Applicants:
Aegis Therapeutics, LLC, Indivior Inc.
Inventors:
Roger CRYSTAL, Phil SKOLNICK, Edward T. MAGGIO
Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Type:
Grant
Filed:
June 7, 2023
Date of Patent:
March 5, 2024
Assignee:
AEGIS THERAPEUTICS, LLC
Inventors:
Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Type:
Grant
Filed:
August 6, 2021
Date of Patent:
September 5, 2023
Assignee:
AEGIS THERAPEUTICS, LLC
Inventors:
Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Type:
Grant
Filed:
October 26, 2022
Date of Patent:
August 8, 2023
Assignee:
AEGIS THERAPEUTICS, LLC
Inventors:
Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.
Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.
Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Type:
Grant
Filed:
May 7, 2020
Date of Patent:
December 7, 2021
Assignee:
AEGIS THERAPEUTICS, LLC
Inventors:
Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Type:
Grant
Filed:
May 22, 2019
Date of Patent:
June 16, 2020
Assignee:
AEGIS THERAPEUTICS, LLC
Inventors:
Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.
Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.
Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a cyclic polypeptide.
Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example octreotide or variant thereof.
Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Abstract: Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi.